1.
Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002; 2(5):
364-371.
2.
Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of
remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; (3): CD005112.
3.
Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's
disease. Cochrane Database Syst Rev. 2008; (1): CD006893.
4.
Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology,
and Management. Clin Transl Gastroenterol. 2016; 7 (1): e135.
5.
Wong U, Cross RK. Primary and secondary nonresponse to infliximab: mechanisms and
countermeasures. Expert Opin Drug Metab Toxicol. 2017; 13 (10): 1039-1046.
6.
Fine S, Papamichael K, Cheifetz AS. Etiology and Management of Lack or Loss of Response to AntiTumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol
(N Y). 2019; 15 (12): 656-665.
7.
Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity
for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 70
(7): 1208-1215.
8.
Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of
infliximab in Crohn's disease. N Engl J Med. 2003; 348 (7): 601-608.
9.
Siljehult F, Ärlestig L, Eriksson C, Rantapää-Dahlqvist S. Concentrations of infliximab and anti-drug
antibodies in relation to clinical response in patients with rheumatoid arthritis. Scand J Rheumatol. 2018;
47 (5): 345-350.
10. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T; RISING study. Impact of trough serum level on
radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis:
results from the RISING study. Mod Rheumatol. 2009; 19 (5) :478-487.
11. Mulleman D, Méric JC, Paintaud G, et al. Infliximab concentration monitoring improves the control of
disease activity in rheumatoid arthritis. Arthritis Res Ther. 2009 ;11 (6): R178.
12. Price S. Rheumatoid arthritis: monitoring serum concentration of infliximab might improve RA disease
control. Nat Rev Rheumatol. 2010 ;6 (2): 66.
13. Schadt S, Hauri S, Lopes F, et al. Are Biotransformation Studies of Therapeutic Proteins Needed?
73
Scientific Considerations and Technical Challenges. Drug Metab Dispos. 2019; 47 (12): 1443-1456.
14. Rogers AS. Adverse drug events: identification and attribution. Drug Intell Clin Pharm. 1987; 21 (11):
915-920.
15. Monti S, Grosso V, Todoerti M, Caporali R. Randomized controlled trials and real-world data: differences
and similarities to untangle literature data. Rheumatology (Oxford). 2018; 57 (57 Suppl 7): vii54-vii58.
16. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996; 312
(7040): 1215-1218.
17. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage
and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007; 10 (5): 326335.
18. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved
issues and future directions. Curr Dir Autoimmun. 2010; 11: 180-210.
19. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis:
subsequent outcome of initial responders. Rheumatology (Oxford). 2007; 46 (7): 1153-1156.
20. Subedi S, Gong Y, Chen Y, Shi Y. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of
efficacy, and adverse events. Drug Des Devel Ther. 2019; 13: 2491-2502.
21. Gill KL, Machavaram KK, Rose RH, Chetty M. Potential Sources of Inter-Subject Variability in
Monoclonal Antibody Pharmacokinetics. Clin Pharmacokinet. 2016; 55 (7): 789-805.
22. Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A
Systematic Review. BioDrugs. 2017; 31 (4): 299-316.
23. Chen C, Hartzema AG, Xiao H, et al. Real-world Pattern of Biologic Use in Patients With Inflammatory
Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive
Therapy. Inflamm Bowel Dis. 2019; 25 (8): 1417-1427.
24. Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in
psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019; 181 (3): 450-458.
25. Lauper K, Finckh A. Predictive factors of treatment persistence in rheumatoid arthritis. Joint Bone Spine.
2020; 87 (6): 531-534.
26. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines
for reporting parallel group randomised trials. BMC Med. 2010; 8: 18.
27. Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evid Based Med. 2016; 21 (4): 125127.
74
28. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol.
1995; 9 (4): 619-632.
29. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid
arthritis in an observational cohort study: comparison of patients according to their eligibility for major
randomized clinical trials. Arthritis Rheum. 2006; 54 (11): 3399-3407.
30. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not
represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012; 10 (9):
1002-e78.
31. Garcia-Doval I, Carretero G, Vanaclocha F, et al. Risk of serious adverse events associated with biologic
and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled
trials. Arch Dermatol. 2012; 148 (4): 463-470.
32. Mason KJ, Barker JNWN, Smith CH, et al. Comparison of Drug Discontinuation, Effectiveness, and
Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatol. 2018; 154
(5): 581-588.
33. Japan Medical Data Center.: ‹https://www.jmdc.co.jp/en/›, accessed 5 January, 2021.
34. Yokoyama K, Yamazaki K, Katafuchi M, Ferchichi S. A Retrospective Claims Database Study on Drug
Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab. Adv Ther.
2016; 33 (11): 1947-1963.
35. Kobayashi T, Udagawa E, Uda A, Hibi T, Hisamatsu T. Impact of immunomodulator use on treatment
persistence in patients with ulcerative colitis: A claims database analysis. J Gastroenterol Hepatol. 2020;
35 (2): 225-232.
36. Sruamsiri R, Iwasaki K, Tang W, Mahlich J. Persistence rates and medical costs of biological therapies
for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatol. 2018;
18 (1): 5.
37. Sugiyama N, Kawahito Y, Fujii T, et al. Treatment Patterns, Direct Cost of Biologics, and Direct Medical
Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims
Data. Clin Ther. 2016; 38 (6): 1359-1375.e1.
38. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the
ACCENT I randomised trial. Lancet. 2002; 359 (9317): 1541-1549.
39. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for
ulcerative colitis. N Engl J Med. 2005; 353 (23): 2462-2476.
75
40. Torii H, Nakagawa H; Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese
patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind,
placebo-controlled multicenter trial. J Dermatol Sci. 2010; 59 (1): 40-49.
41. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of
rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant
Therapy Study Group. N Engl J Med. 2000; 343 (22): 1594-1602.
42. Eshuis EJ, Peters CP, van Bodegraven AA, et al. Ten years of infliximab for Crohn's disease: outcome in
469 patients from 2 tertiary referral centers. Inflamm Bowel Dis. 2013; 19 (8): 1622-1630.
43. Juillerat P, Sokol H, Froehlich F, et al. Factors associated with durable response to infliximab in Crohn's
disease 5 years and beyond: a multicenter international cohort. Inflamm Bowel Dis. 2015; 21 (1): 60-70.
44. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis:
outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol.
2010; 105 (12): 2617-2625.
45. Sbidian E, Mezzarobba M, Weill A, Coste J, Rudant J. Persistence of treatment with biologics for patients
with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health
Insurance database (SNIIRAM). Br J Dermatol. 2019; 180 (1): 86-93.
46. Flouri I, Markatseli TE, Voulgari PV, et al. Comparative effectiveness and survival of infliximab,
adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low
rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014; 43 (4): 447-457.
47. Souto A, Maneiro JR, Gómez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies
in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care
databases. Rheumatology (Oxford). 2016; 55 (3): 523-534.
48. Emery P, Vlahos B, Szczypa P, et al. Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in
Patients with Rheumatoid Arthritis. J Rheumatol. 2020; 47 (4): 493-501.
49. van der Schoot LS, van den Reek JMPA, Groenewoud JMM, et al. Female patients are less satisfied with
biological treatment for psoriasis and experience more side-effects than male patients: results from the
prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2019; 33 (10): 1913-1920.
50. Hambardzumyan K, Hermanrud C, Marits P, et al. Association of female sex and positive rheumatoid
factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid
arthritis: results from the SWEFOT trial population. Scand J Rheumatol. 2019; 48 (5): 362-366.
51. Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L. Treatment Persistence for
76
Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. Inflamm Bowel
Dis. 2017; 23 (6): 976-985.
52. Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P. Predictors of response to
anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from
the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008; 47 (4): 495-499.
53. Mahlich J, Sruamsiri R. Persistence with biologic agents for the treatment of rheumatoid arthritis in
Japan. Patient Prefer Adherence. 2016; 10: 1509-1519.
54. Bonafede MMK, McMorrow D, Proudfoot C, Shinde S, Kuznik A, Chen CI. Treatment Persistence and
Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy. Am
Health Drug Benefits. 2018; 11 (4): 192-202.
55. Maniadakis N, Toth E, Schiff M, et al. A Targeted Literature Review Examining Biologic Therapy
Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs,
Driving Factors, and Consequences. Adv Ther. 2018; 35 (9): 1333-1355.
56. Mattey DL, Brownfield A, Dawes PT. Relationship between pack-year history of smoking and response
to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol. 2009; 36 (6): 11801187.
57. Gil-Candel M, Gascón-Cánovas JJ, Urbieta-Sanz E, Rentero-Redondo L, Onteniente-Candela M,
Iniesta-Navalón C. Comparison of drug survival between infliximab and adalimumab in inflammatory
bowel disease. Int J Clin Pharm. 2020; 42 (2): 500-507.
58. Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who
switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007;
66 (7): 893-899.
59. Fleischmann R, Goldman JA, Leirisalo-Repo M, et al. Infliximab efficacy in rheumatoid arthritis after an
inadequate response to etanercept or adalimumab: results of a target-driven active switch study. Curr Med
Res Opin. 2014; 30 (11): 2139-2149.
60. Umeda M, Koga T, Ichinose K, et al. Efficacy of infliximab as a switched biologic in rheumatoid arthritis
patients in daily clinical practice. Immunol Med. 2018; 41 (4): 181-186.
61. Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D. The effectiveness of anti-TNF-alpha therapies
when used sequentially in rheumatoid arthritis patients: a systematic review and metaanalysis. Rheumatology (Oxford). 2010; 49 (12): 2313-2321.
62. Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies
77
for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α
inhibitors. Arthritis Res Ther. 2011; 13 (1): R25.
63. Oei HB, Hooker RS, Cipher DJ, Reimold A. High rates of stopping or switching biological medications
in veterans with rheumatoid arthritis. Clin Exp Rheumatol. 2009; 27 (6): 926-934.
64. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based
registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry
(PSOLAR). J Eur Acad Dermatol Venereol. 2016; 30 (7): 1148-1158.
65. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of
four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a
randomized, controlled trial. Arthritis Rheum. 2005; 52 (11): 3381-3390.
66. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity
in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum
Dis. 2010; 69 (7): 1286-1291.
67. Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic Review of Effects of
Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel
Disease. Gastroenterology. 2015; 149 (7): 1716-1730.
68. Hashimoto M, Furu M, Yamamoto W, et al. Factors associated with the achievement of biological
disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort
study. Arthritis Res Ther. 2018; 20 (1): 165.
69. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha
monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant
methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999; 354 (9194): 19321939.
70. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab
after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004; 2 (7): 542553.
71. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of
infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001; 357 (9271): 18421847.
72. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J
Gastroenterol. 2011; 106 (4): 685-698.
78
73. Ebina K, Hashimoto M, Yamamoto W, et al. Drug retention and discontinuation reasons between seven
biologics in patients with rheumatoid arthritis -The ANSWER cohort study. PLoS One. 2018; 13 (3):
e0194130.
74. Plasencia C, Jurado T, Villalba A, et al. Effect of Infliximab Dose Increase in Rheumatoid Arthritis at
Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions. Front Med (Lausanne).
2015; 2: 71.
75. Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for
rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017; 13 (12): 707-718.
76. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring
of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor
necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006; 54 (12): 3782-3789.
77. Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of longterm treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011; 50 (8): 1445-1452.
78. Tzaban S, Massol RH, Yen E, et al. The recycling and transcytotic pathways for IgG transport by FcRn
are distinct and display an inherent polarity. J Cell Biol. 2009; 185 (4): 673-684.
79. Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs. 2011; 3 (5): 422-430.
80. Masui S, Yonezawa A, Izawa K, et al. Plasma infliximab monitoring contributes to optimize Takayasu
arteritis treatment: a case report. J Pharm Health Care Sci. 2019;5:9.
81. Terao C, Hashimoto M, Yamamoto K, et al. Three groups in the 28 joints for rheumatoid arthritis
synovitis--analysis using more than 17,000 assessments in the KURAMA database. PLoS One. 2013; 8
(3): e59341.
82. Iwamoto N, Shimada T, Umino Y, et al. Selective detection of complementarity-determining regions of
monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation
limited proteolysis. Analyst. 2014; 139 (3): 576-580.
83. Iwamoto N, Yokoyama K, Takanashi M, Yonezawa A, Matsubara K, Shimada T. Verification between
Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis
in Human Serum. Curr Pharm Biotechnol. 2018; 19 (6): 495-505.
84. Iwamoto N, Takanashi M, Yokoyama K, et al. Multiplexed monitoring of therapeutic antibodies for
inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS. J Immunol
Methods. 2019; 472: 44-54.
85. Reinisch W, Jahnsen J, Schreiber S, et al. Evaluation of the Cross-reactivity of Antidrug Antibodies to CT79
P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both
Agents. BioDrugs. 2017; 31 (3): 223-237.
86. Shibata H, Nishimura K, Miyama C, et al. Comparison of different immunoassay methods to detect
human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes. J
Immunol Methods. 2018; 452: 73-77.
87. Pallagi-Kunstár É, Farkas K, Szepes Z, et al. Utility of serum TNF-α, infliximab trough level, and
antibody titers in inflammatory bowel disease. World J Gastroenterol. 2014; 20 (17): 5031-5035.
88. Dannepond C, Maruani A, Machet L, Ternant D, Paintaud G, Samimi M. Serum infliximab
concentrations in psoriatic patients treated with infliximab: a systematic review. Acta Derm Venereol.
2015; 95 (4): 401-406.
89. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for
patients with inflammatory bowel disease. Gastroenterology. 2015; 148 (7): 1320-9.e3.
90. Warman A, Straathof JW, Derijks LJ. Therapeutic drug monitoring of infliximab in inflammatory bowel
disease patients in a teaching hospital setting: results of a prospective cohort study. Eur J Gastroenterol
Hepatol. 2015; 27 (3): 242-248.
91. Vallejo-Yagüe E, Keystone EC, Kandhasamy S, Micheroli R, Finckh A, Burden AM. Primary and
secondary non-response: in need of operational definitions in observational studies. Ann Rheum Dis.
2021; 80 (8): 961-964.
92. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels,
pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with
rheumatoid arthritis. Ann Rheum Dis. 2005; 64 (5): 704-707.
93. Güven E, Duus K, Lydolph MC, Jørgensen CS, Laursen I, Houen G. Non-specific binding in solid phase
immunoassays for autoantibodies correlates with inflammation markers. J Immunol Methods. 2014; 403
(1-2): 26-36.
94. Jourdil JF, Lebert D, Gautier-Veyret E, et al. Infliximab quantitation in human plasma by liquid
chromatography-tandem mass spectrometry: towards a standardization of the methods?. Anal Bioanal
Chem. 2017; 409 (5): 1195-1205.
95. U.S. Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry.: ‹
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-methodvalidation-guidance-industry›, accessed 5 January, 2021.
96. Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug
80
antibodies in inflammatory bowel disease: Case series and review of literature. World J Gastrointest
Pharmacol Ther. 2017; 8 (3): 155-161.
97. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric
antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010; 105 (5):
1133-1139.
98. Keystone EC, Rampakakis E, Movahedi M, et al. Toward Defining Primary and Secondary Nonresponse
in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI
Registries. J Rheumatol. 2020; 47 (4): 510-517.
99. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to
clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 2002; 46 (6): 1451-1459.
100. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels,
pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with
rheumatoid arthritis. Ann Rheum Dis. 2005; 64 (5): 704-707.
101. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified
disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective
longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38 (1): 44-48.
102. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of
rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Ann Rheum Dis. 2020; 79 (6): 685-699.
103. Takeuchi T, Miyasaka N, Tatsuki Y, et al. Inhibition of plasma IL-6 in addition to maintenance of an
efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid
arthritis: analysis of the RISING Study. Ann Rheum Dis. 2012; 71 (9): 1583-1585.
104. Takasugi K, Nishida K, Natsumeda M, Yamashita M, Yamamoto W, Ezawa K. IL-6 is an independent
predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid
arthritis. Mod Rheumatol. 2018; 28 (3): 452-460.
105. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for
rheumatoid arthritis. Nat Rev Rheumatol. 2013; 9 (3): 164-172.
106. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins
following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999; 163 (3): 1521-1528.
107. Dain L, Braun-Moscovici Y, Baum E, Nahir AM, Hoffer E. Modification of neutrophil function by
81
plasma of rheumatoid arthritis patients treated with infliximab. Clin Exp Rheumatol. 2006; 24 (1): 38-44.
108. Takeuchi T. Treatment of rheumatoid arthritis with biological agents - as a typical and common immunemediated inflammatory disease. Proc Jpn Acad Ser B Phys Biol Sci. 2017; 93 (8): 600-608.
109. Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol.
2006; 24 (10): 1241-1252.
110. Jenkins N, Murphy L, Tyther R. Post-translational modifications of recombinant proteins: significance
for biopharmaceuticals. Mol Biotechnol. 2008; 39 (2): 113-118.
111. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm
Sci. 2008; 97 (7): 2426-2447.
112. ICH. S6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals.: ‹
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/s6r1-preclinical
safety-
evaluation-biotechnology-derived-pharmaceuticals›, accessed 22 June, 2022.
113. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant
human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997; 337 (3): 141-147.
114. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of
action: a comprehensive review. Pharmacol Ther. 2008; 117 (2): 244-279.
115. Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of
rheumatoid arthritis. Cochrane Database Syst Rev. 2013; (5): CD004525.
116. Zhao S, Mysler E, Moots RJ. Etanercept for the treatment of rheumatoid arthritis. Immunotherapy. 2018;
10 (6): 433-445.
117. Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of
etanercept in healthy volunteers. Ann Pharmacother. 2000; 34 (2): 161-164.
118. Kawai S, Sekino H, Yamashita N, Tsuchiwata S, Liu H, Korth-Bradley JM. The comparability of
etanercept pharmacokinetics in healthy Japanese and American subjects. J Clin Pharmacol. 2006; 46 (4):
418-423.
119. Takeuchi T, Miyasaka N, Kawai S, et al. Pharmacokinetics, efficacy and safety profiles of etanercept
monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials. Mod
Rheumatol. 2015; 25 (2): 173-186.
120. Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic
antibodies. Mass Spectrom Rev. 2009; 28 (1): 147-176.
121. Lee JH, Yeo J, Park HS, et al. Biochemical characterization of a new recombinant TNF receptor-hyFc
82
fusion protein expressed in CHO cells. Protein Expr Purif. 2013; 87 (1): 17-26.
122. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted
protein of activated lymphocytes. Scand J Immunol. 2001; 54 (3): 249-264.
123. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the
enzyme. Curr Med Chem. 2009; 16 (23): 2943-2951.
124. Hampson G, Ward TH, Cummings J, et al. Validation of an ELISA for the determination of rituximab
pharmacokinetics in clinical trials subjects. J Immunol Methods. 2010; 360 (1-2): 30-38.
125. Iwamoto N, Yokoyama K, Takanashi M, Yonezawa A, Matsubara K, Shimada T. Application of nSMOL
coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and
Abatacept in human serum. Pharmacol Res Perspect. 2018; 6 (4): e00422.
126. Hamuro LL, Kishnani NS. Metabolism of biologics: biotherapeutic proteins. Bioanalysis. 2012; 4 (2):
189-195.
127. Neubert H, Alley SC, Lee A, et al. 2020 White Paper on Recent Issues in Bioanalysis: BMV of Hybrid
Assays, Acoustic MS, HRMS, Data Integrity, Endogenous Compounds, Microsampling and
Microbiome (Part 1 - Recommendations on Industry/Regulators Consensus on BMV of Biotherapeutics
by LCMS, Advanced Application in Hybrid Assays, Regulatory Challenges in Mass Spec, Innovation in
Small Molecules, Peptides and Oligos). Bioanalysis. 2021; 13 (4): 203-238.
128. Chu KO, Liu DT, Chan KP, et al. Quantification and structure elucidation of in vivo bevacizumab
modification in rabbit vitreous humor after intravitreal injection. Mol Pharm. 2012; 9 (12): 3422-3433.
129. Otani Y, Yonezawa A, Tsuda M, et al. Time-Dependent Structural Alteration of Rituximab Analyzed by
LC/TOF-MS after a Systemic Administration to Rats. PLoS One. 2017; 12 (1): e0169588.
130. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human
TNF beta complex: implications for TNF receptor activation. Cell. 1993; 73 (3): 431-445.
131. Mukai Y, Nakamura T, Yoshikawa M, et al. Solution of the structure of the TNF-TNFR2 complex. Sci
Signal. 2010; 3 (148): ra83.
132. Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018; 9 (1): 1532.
133. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7 (9):
715-725.
134. Aertgeerts K, Ye S, Shi L, et al. N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on
enzyme activity, homodimer formation, and adenosine deaminase binding. Protein Sci. 2004; 13 (1):
83
145-154.
135. Zhong J, Kankanala S, Rajagopalan S. Dipeptidyl peptidase-4 inhibition: insights from the bench and
recent clinical studies. Curr Opin Lipidol. 2016; 27 (5): 484-492.
136. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology
and mechanisms of action. Diabetes Care. 2007; 30 (6): 1335-1343.
137. Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev
Endocrinol. 2020; 16 (11): 642-653.
138. Broxmeyer HE, Hoggatt J, O'Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colonystimulating factor activity and stress hematopoiesis. Nat Med. 2012; 18 (12): 1786-1796.
139. Zell M, Husser C, Staack RF, et al. In Vivo Biotransformation of the Fusion Protein TetranectinApolipoprotein A1 Analyzed by Ligand-Binding Mass Spectrometry Combined with Quantitation by
ELISA. Anal Chem. 2016; 88 (23): 11670-11677.
140. Schadt S, Husser C, Staack RF, et al. The In Vitro Biotransformation of the Fusion Protein TetranectinApolipoprotein A1. Sci Rep. 2019; 9 (1): 4074.
141. Waumans Y, Baerts L, Kehoe K, Lambeir AM, De Meester I. The Dipeptidyl Peptidase Family, Prolyl
Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease,
Including Atherosclerosis. Front Immunol. 2015; 6: 387.
84
...
論文の公開元へ
